Expression Profile and Implications of ACE2; The Receptor for New SARS-CoV-2
Abstract
Expansion of novel coronavirus disease 2019 (COVID-19) involves various risk factors including clinical, genetic, demographic and environmental manifestation but they are insufficient to explain disease pathogenesis. With patients ranging from completely asymptomatic to many suffering mild to severe illness, indicates that COVID- 19 should better be studied at genetic level as different genetic backgrounds predispose to variability in infection susceptibility. Recently, it is recognized that severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) binds and internalized by the host cells through cell surface receptors angiotensin-converting enzyme 2 (ACE2), which is expressed significantly in variety of human tissues particularly in the lower and upper respiratory tract. To scrutinize the expression profiles and clinical implications of ACE2 gene in humans, literature was extensively reviewed. In common, various studies reported that ACE2 receptor protein is highly conserved among different species, the expression pattern is tissue specific mainly observed in cardiovascular system, breast cells, testis, adipose tissue, kidney, lymphocytes and gastrointestinal system other than the upper and lower respiratory tract. This significant expression makes these organs vulnerable to SARS-CoV-2 virus and hence many comorbidities may be observed during the course of infection. The present review on expression profile of ACE2 not only proposes potential clues for COVID-19 pathogenesis but also designate clinical values of ACE2 gene in heterogeneous disorders.
References
Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?. Clinical Chemistry and Laboratory Medicine (CCLM). 2020; 58: 1. (ahead-of-print).
Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Annals of Translational Medicine. 2020; 8: 497.
Fu J, Zhou B, Zhang L, Balaji KS, Wei C, Liu X, et al. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. Molecular Biology Reports. 2020; 14: 1-10.
Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males? International Journal of Molecular Sciences. 2020; 21: 3474.
Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. Journal of virology. 2011; 85: 4122-34.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181: 271-80.
Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer discovery. 2014; 4: 1310-25.
Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer discovery. 2020; 10: 779-82.
Swärd P, Edsfeldt A, Reepalu A, Jehpsson L, Rosengren BE, Karlsson MK. Age and sex differences in soluble ACE2 may give insights for COVID-19. Critical Care. 2020; 24: 1-3.
Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-Converting Enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in Coronavirus Disease 2019. In Mayo Clinic Proceedings. Elsevier. 2020; 95: 1222-30.
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation research. 2000;
: e1-9.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270-3.
Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS letters. 2002; 532:107-10.
Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infectious diseases of poverty. 2020; 9: 1-7.
Sungnak W, Huang N, Bécavin C, Berg M, Network HC. SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways. arXiv preprint arXiv: 2003.06122. 2020.
Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International journal of oral science. 2020; 12: 1-5.
Henry BM, De Oliveira MH, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 2020; 58: 1021-8.
Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111: 2605-10.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. 2020; 395: 1417-8.
Fan C, Li K, Ding Y, Lu WL, Wang J. ACE2 expression in kidney and testis may cause kidney and testis damage after 2019- nCoV infection. MedRxiv. 2020.
Wang Z, Xu X. scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, Leydig and Sertoli cells. Cells. 2020; 9: 920.
Shen Q, Xiao X, Aierken A, Yue W, Wu X, Liao M, et al. The ACE2 expression in Sertoli cells and germ cells may cause male reproductive disorder after SARS-CoV-2 infection. Journal of Cellular and Molecular Medicine. 2020; 24: 9472-7.
Almasry SM, Hassan ZA, Elsaed WM, Elbastawisy YM. Structural evaluation of the peritubular sheath of rat's testes after administration of ribavirin: A possible impact on the testicular function. International journal of immunopathology and pharmacology. 2017; 30: 282-96.
Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020; 370: eabd4570.
Shirvani E, Samal SK. Newcastle Disease Virus as a Vaccine Vector for SARS-CoV-2. Pathogens. 2020; 9: 619.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020 ; 382: 1708-20.
Al-Baadani AM, Elzein FE, Alhemyadi SA, Khan OA, Albenmousa AH, Idrees MM. Characteristics and outcome of viral pneumonia caused by influenza and Middle East respiratory syndrome-coronavirus infections: a 4-year experience from a tertiary care center. Annals of thoracic medicine. 2019; 14: 179.
Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in China: results from the China hypertension survey, 2012–2015. Circulation. 2018; 137: 2344-56.
LuJ,LuY,WangX,LiX,LindermanGC,WuC,etal. Prevalence, awareness, treatment, and control of hypertension in China: data from 1· 7 million adults in a population-based screening study (China PEACE Million Persons Project). The Lancet. 2017; 390: 2549-58.
Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature Medicine. 2020; 26: 506-10.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020; 395: 1054-62.
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID- 19) infection: a systematic review and meta-analysis. International journal of infectious diseases. 2020; 395: 1054-62.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 2020; 323: 2052-59.
Fu J, Zhou B, Zhang L, Balaji KS, Wei C, Liu X, et al. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. Molecular Biology Reports. 2020; 47: 4383-92.
Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infectious diseases of poverty. 2020; 9: 1-7.
Pinto BG, Oliveira AE, Singh Y, Jimenez L, Gonçalves AN,
Ogava RL, et al. ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID- 19. MedRxiv. 2020.
Dutta S, Sengupta P. SARS-CoV-2 and male infertility: possible multifaceted pathology. Reproductive Sciences. 2020; 10: 1-4.
Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. The American journal of emergency medicine. 2020; 38: 1504-07.
Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Molecular and cellular endocrinology. 2009; 302: 193-202.
Dietz JR, Moran MS, Isakoff SJ, Kurtzman SH, Willey SC, Burstein HJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast cancer research and treatment. 2020; 181: 487-97.
